Halozyme Therapeutics, Inc. (HALO) 2021年年度报告「NASDAQ」.pdf

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-KANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31,2021ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the tr

2、ansition period from to Commission File Number 001-32335_HALOZYME THERAPEUTICS,INC.(Exact name of registrant as specified in its charter)_Delaware 88-0488686(State or other jurisdiction of incorporation or organization)(I.R.S.Employer Identification No.)11388 Sorrento Valley Road 92121San Diego(Zip

3、Code)CA(Address of principal executive offices)(858)794-8889(Registrants telephone number,including area code)Securities registered under Section 12(b)of the Act:Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which RegisteredCommon Stock,$0.001 Par ValueHALOThe NASDAQ Stock Market,LLCS

4、ecurities registered under Section 12(g)of the Act:NoneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes NoIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d)of the Act.Yes No

5、Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to such filin

6、g requirementsfor the past 90 days.Yes NoIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (232.405 of this chapter)during the preceding 12 months (or for such shorter period that the